US arm of Glenmark Pharmaceuticals has launched the fixed-dose combination (FDC) therapy for seasonal allergic rhinitis in the US market. This Ryaltris nasal spray will be distributed by Hikma Pharmaceuticals, a British drug manufacturer.

As per media reports, the wholesale acquisition cost price for Ryaltris is to be kept around USD 210. The company has said that patients would have to pay around USD 49 considering the co-pay mechanism. Currently, Ryaltris is not covered under the insurance.

Notably, in 2018, nearly 24 million people in the US were diagnosed with seasonal allergic rhinitis (also called hay fever). Of this, approximately 8 per cent (19.2 million) were adults, and 7 per cent (5.2 million) were children.
Presently, only one drug combines fluticasone propionate with azelastine hydrochloride. It is marketed in some countries by US-based drug maker Mylan.

A study suggests that the total market size of Allergic Rhinitis therapies in the US is expected to grow at a compound annual growth rate (CAGR) of 3.8 per cent from the period 2018-2030.

Headquartered in Mumbai, Glenmark was founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient (API) manufacturer. Glenmark enjoys a three-year exclusivity period for the drug Ryaltris. It has chalked out plans to launch Ryaltris in global markets, including Australia, Poland, Italy, South Africa, Russia, Ecuador etc.